Literature DB >> 21041303

Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.

Phillip C Delekta1, Ingrid J Apel, Shufang Gu, Katy Siu, Yoshiyuki Hattori, Linda M McAllister-Lucas, Peter C Lucas.   

Abstract

Thrombin is a potent modulator of endothelial function and, through stimulation of NF-κB, induces endothelial expression of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). These cell surface adhesion molecules recruit inflammatory cells to the vessel wall and thereby participate in the development of atherosclerosis, which is increasingly recognized as an inflammatory condition. The principal receptor for thrombin on endothelial cells is protease-activated receptor-1 (PAR-1), a member of the G protein-coupled receptor superfamily. Although it is known that PAR-1 signaling to NF-κB depends on initial PKC activation, the subsequent steps leading to stimulation of the canonical NF-κB machinery have remained unclear. Here, we demonstrate that a complex of proteins containing CARMA3, Bcl10, and MALT1 links PAR-1 activation to stimulation of the IκB kinase complex. IκB kinase in turn phosphorylates IκB, leading to its degradation and the release of active NF-κB. Further, we find that although this CARMA3·Bcl10·MALT1 signalosome shares features with a CARMA1-containing signalosome found in lymphocytes, there are significant differences in how the signalosomes communicate with their cognate receptors. Specifically, whereas the CARMA1-containing lymphocyte complex relies on 3-phosphoinositide-dependent protein kinase 1 for assembly and activation, the CARMA3-containing endothelial signalosome functions completely independent of 3-phosphoinositide-dependent protein kinase 1 and instead relies on β-arrestin 2 for assembly. Finally, we show that thrombin-dependent adhesion of monocytes to endothelial cells requires an intact endothelial CARMA3·Bcl10·MALT1 signalosome, underscoring the importance of the signalosome in mediating one of the most significant pro-atherogenic effects of thrombin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041303      PMCID: PMC3009869          DOI: 10.1074/jbc.M110.158949

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.

Authors:  P C Lucas; M Yonezumi; N Inohara; L M McAllister-Lucas; M E Abazeed; F F Chen; S Yamaoka; M Seto; G Nunez
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

2.  An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways.

Authors:  N Inohara; T Koseki; J Lin; L del Peso; P C Lucas; F F Chen; Y Ogura; G Núñez
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

Review 3.  Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling.

Authors:  Sudha K Shenoy; Robert J Lefkowitz
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

Review 4.  CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.

Authors:  Margot Thome
Journal:  Nat Rev Immunol       Date:  2004-05       Impact factor: 53.106

5.  A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells.

Authors:  K A O'Connell; M Edidin
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

6.  Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38.

Authors:  L V Madrid; M W Mayo; J Y Reuther; A S Baldwin
Journal:  J Biol Chem       Date:  2001-03-20       Impact factor: 5.157

7.  Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB.

Authors:  L V Madrid; C Y Wang; D C Guttridge; A J Schottelius; A S Baldwin; M W Mayo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1.

Authors:  P J O'Brien; N Prevost; M Molino; M K Hollinger; M J Woolkalis; D S Woulfe; L F Brass
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

Review 9.  Thrombin signalling and protease-activated receptors.

Authors:  S R Coughlin
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 10.  Thrombin and phenotypic modulation of the endothelium.

Authors:  Takashi Minami; Akira Sugiyama; Sheng-Qian Wu; Ruhul Abid; Tatsuhiko Kodama; William C Aird
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-09       Impact factor: 8.311

View more
  32 in total

1.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

2.  The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli.

Authors:  Huan Qiao; Yan Liu; Ruth A Veach; Lukasz Wylezinski; Jacek Hawiger
Journal:  J Biol Chem       Date:  2014-06-23       Impact factor: 5.157

Review 3.  From MALT lymphoma to the CBM signalosome: three decades of discovery.

Authors:  Shaun Rosebeck; Aasia O Rehman; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 4.  Regulation of NF-κB by the CARD proteins.

Authors:  Changying Jiang; Xin Lin
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 5.  MALT1 protease: a new therapeutic target in B lymphoma and beyond?

Authors:  Linda M McAllister-Lucas; Mathijs Baens; Peter C Lucas
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

6.  Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.

Authors:  Yong Li; Shengping Huang; Xuan Huang; Xiuzhen Li; Adrian Falcon; Adele Soutar; Frederic Bornancin; Zhisheng Jiang; Hong-Bo Xin; Mingui Fu
Journal:  Cell Signal       Date:  2018-06-18       Impact factor: 4.315

Review 7.  The Paracaspase MALT1.

Authors:  Janna Hachmann; Guy S Salvesen
Journal:  Biochimie       Date:  2015-09-16       Impact factor: 4.079

8.  MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Authors:  Linda R Klei; Dong Hu; Robert Panek; Danielle N Alfano; Rachel E Bridwell; Kelly M Bailey; Katherine I Oravecz-Wilson; Vincent J Concel; Emily M Hess; Matthew Van Beek; Phillip C Delekta; Shufang Gu; Simon C Watkins; Adrian T Ting; Peter J Gough; Kevin P Foley; John Bertin; Linda M McAllister-Lucas; Peter C Lucas
Journal:  Cell Rep       Date:  2016-09-27       Impact factor: 9.423

Review 9.  β-Arrestins in the immune system.

Authors:  Dianhua Jiang; Ting Xie; Jiurong Liang; Paul W Noble
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

10.  MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10.

Authors:  Jibin Lin; Shaolin He; Xinghui Sun; Gregory Franck; Yihuan Deng; Dafeng Yang; Stefan Haemmig; A K M Wara; Basak Icli; Dazhu Li; Mark W Feinberg
Journal:  FASEB J       Date:  2016-06-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.